Evidence map›Paper›PMID 41220404›Full record

ArticleJournal of inflammation research2025

Prognostic Value of C-Reactive Protein, Procalcitonin, and Interferon-Alpha in COVID-19 and Their Association with PANoptosis: A Cohort Study in Guangxi, China.

Li-Jun Ning, Mei-Qiong Liu, Zhong-Sheng Jiang, Xian-Qiu Wu, Xiao-Yuan Wang, Xue-Jun Qin, Tao Gan, Shi-Fu Tang, Guang-Yu Lv, Ying Wu

Abstract read
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Jun Ning *Liuzhou Key Laboratory of Infection Disease and Immunology, Research Center of Medical Sciences, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Mei-Qiong Liu *Department of Critical Care Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Zhong-Sheng Jiang *Department of Infectious Diseases Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Xian-Qiu WuDepartment of Cardiothoracic Surgery, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Xiao-Yuan WangDepartment of Critical Care Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Xue-Jun QinDepartment of Respiratory and Critical Care Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Tao GanDepartment of Emergency Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Shi-Fu TangDepartment of Medical laboratory Science, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Guang-Yu LvDepartment of Critical Care Medicine, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.
Ying WuLiuzhou Key Laboratory of Infection Disease and Immunology, Research Center of Medical Sciences, Liuzhou People's Hospital Affiliated to Guangxi Medical University, Liuzhou, Guangxi, 545006, People's Republic of China.ORCID 0000-0002-7070-2644

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Numerous biomarkers of COVID-19 severity have been studied recently, while their relevance in the post-COVID-19 era requires further validation. This study sought to identify reliable biomarkers within a single cohort through a comprehensive comparative analysis and to investigate the underlying molecular mechanisms. Material and Methods: In this prospective, observational cohort study, we comprehensively assessed 41 markers in 97 COVID-19 pneumonia patients and 53 healthy volunteers. Receiver operating characteristics and Kaplan-Meier curves were plotted to determine the predictive value of effective biomarkers. Subsequently, flow cytometry, immunofluorescence, and Western blot analysis were conducted to evaluate the inflammatory cell death induced by the identified biomarkers in peripheral blood cells. Results: Based on the screening, plasma IL-6, IL-8, IL-10, IFN-α, PCT, and CRP at hospital admission were highly associated with disease severity ( Conclusion: The value of IL-6, IL-8, IL-10, IFN-α, PCT, and CRP in predicting the severity of COVID-19 was further verified in our study, and superior to novel biomarkers. Our data confirmed for the first time that CRP, PCT, and/or IFN-α triggers PANoptosis in lymphocytes, neutrophils, and platelets, which may prompt severe progression in COVID-19 patients.

Indexed as

COVID-19C-reactive proteininterferon alphaPANoptosisprocalcitonin

Identifiers

PMID41220404
PMCPMC12599207

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.